Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RQ3033
- Development stage
- Discontinued
- Lead developer
- Walvax Biotechnology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
RQ3033 is an mRNA-based COVID-19 vaccine developed by Walvax Biotechnology in collaboration with Fudan University and Shanghai RNACure Biopharma. It is specifically designed to target the SARS-CoV-2 Omicron XBB.1.5 variant. The vaccine utilizes mRNA technology to encode the viral spike protein, which, upon administration, is translated by host cells to stimulate the production of neutralizing antibodies and T-cell responses against the virus. In December 2023, RQ3033 was granted emergency use authorization (EUA) by the National Medical Products Administration (NMPA) in China for use as a booster dose to address the prevalence of XBB subvariants.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on RQ3033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RQ3033.